Abid Shahab, Jafri Wasim, Zaman Maseeh Uz, Bilal Rakhshanda, Awan Safia, Abbas Aamir
Shahab Abid, Wasim Jafri, Safia Awan, Aamir Abbas, Department of Medicine, Aga Khan University, Karachi 74800, Pakistan.
World J Gastrointest Pharmacol Ther. 2017 Feb 6;8(1):74-80. doi: 10.4292/wjgpt.v8.i1.74.
To study the effect of itopride on gastric accommodation, gastric emptying and drinking capacity in functional dyspepsia (FD).
Randomized controlled trial was conducted to check the effect of itopride on gastric accommodation, gastric emptying, capacity of tolerating nutrient liquid and symptoms of FD. We recruited a total of 31 patients having FD on the basis of ROME III criteria. After randomization, itopride was received by 15 patients while 16 patients received placebo. Gastric accommodation was determined using Gastric Scintigraphy. C labeled octanoic breadth test was performed to assess gastric emptying. Capacity of tolerating nutrient liquid drink was checked using satiety drinking capacity test. The intervention group comprised of 150 mg itopride. Patients in both arms were followed for 4 wk.
Mean age of the recruited participant 33 years (SD = 7.6) and most of the recruited individuals, ., 21 (67.7%) were males. We found that there was no effect of itopride on gastric accommodation as measured at different in volumes in the itopride and control group with the empty stomach ( = 0.14), at 20 min ( = 0.38), 30 min ( = 0.30), 40 min ( 0.43), 50 min ( = 0.50), 60 min ( 0.81), 90 min ( 0.25) and 120 min ( 0.67). Gastric emptying done on a sub sample ( = 11) showed no significant difference ( = 0.58) between itopride and placebo group. There was no significant improvement in the capacity to tolerate liquid in the itopride group as compared to placebo ( = 0.51). Similarly there was no significant improvement of symptoms as assessed through a composite symptom score ( = 0.74). The change in QT interval in itopride group was not significantly different from placebo (0.10).
Our study found no effect of itopride on gastric accommodation, gastric emptying and maximum tolerated volume in patients with FD.
研究伊托必利对功能性消化不良（FD）患者胃容纳功能、胃排空及饮水量的影响。
采用随机对照试验，观察伊托必利对FD患者胃容纳功能、胃排空、营养液耐受量及症状的影响。根据罗马III标准，共纳入31例FD患者。随机分组后，15例患者接受伊托必利治疗，16例患者接受安慰剂治疗。采用胃闪烁扫描法测定胃容纳功能。进行¹³C标记辛酸呼气试验评估胃排空。通过饱腹感饮水量试验检测营养液耐受量。干预组给予150 mg伊托必利。两组患者均随访4周。
纳入参与者的平均年龄为33岁（标准差 = 7.6），大部分纳入者（即21例，67.7%）为男性。我们发现，在空腹状态下（P = 0.14）、20分钟时（P = 0.38）、30分钟时（P = 0.30）、40分钟时（P = 0.43）、50分钟时（P = 0.50）、60分钟时（P = 0.81）、90分钟时（P = 0.25）和120分钟时（P = 0.67），伊托必利组与对照组在不同容量下测量的胃容纳功能方面无差异。对一个亚样本（n = 11）进行的胃排空检测显示，伊托必利组与安慰剂组之间无显著差异（P = 0.58）。与安慰剂组相比，伊托必利组的液体耐受能力无显著改善（P = 0.51）。同样，通过综合症状评分评估的症状也无显著改善（P = 0.74）。伊托必利组的QT间期变化与安慰剂组无显著差异（P = 0.10）。
我们的研究发现，伊托必利对FD患者的胃容纳功能、胃排空及最大耐受量无影响。
